Toward development of a surface-enhanced Raman scattering (SERS)-based cancer diagnostic immunoassay panel

Proteomic analyses of readily obtained human fluids ( e.g. , serum, urine, and saliva) indicate that the diagnosis of complex diseases will be enhanced by the simultaneous measurement of multiple biomarkers from such samples. This paper describes the development of a nanoparticle-based multiplexed p...

Full description

Saved in:
Bibliographic Details
Published in:Analyst (London) 2013-01, Vol.138 (2), p.41-416
Main Authors: Granger, Jennifer H, Granger, Michael C, Firpo, Matthew A, Mulvihill, Sean J, Porter, Marc D
Format: Article
Language:English
Subjects:
Adenocarcinoma - diagnosis
Biomarkers
Biomarkers, Tumor - blood
CA-19-9 Antigen - blood
Cancer
Diagnosis
Diagnostic systems
Diseases
Gold
Humans
Immunoassay
Matrix Metalloproteinase 7 - blood
Metal Nanoparticles
Nanostructure
Pancreatic Neoplasms - diagnosis
Panels
Prognosis
Proteomics
Raman scattering
Spectrum Analysis, Raman
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Proteomic analyses of readily obtained human fluids ( e.g. , serum, urine, and saliva) indicate that the diagnosis of complex diseases will be enhanced by the simultaneous measurement of multiple biomarkers from such samples. This paper describes the development of a nanoparticle-based multiplexed platform that has the potential for simultaneous read-out of large numbers of biomolecules. For this purpose, we have chosen pancreatic adenocarcinoma (PA) as a test bed for diagnosis and prognosis. PA is a devastating form of cancer in which an estimated 86% of diagnoses resulted in death in the United States in 2010. The high mortality rate is due, in part, to the asymptomatic development of the disease and the dearth of sensitive diagnostics available for early detection. One promising route lies in the development of a serum biomarker panel that can generate a signature unique to early stage PA. We describe the design and development of a proof-of-concept PA biomarker immunoassay array coupled with surface-enhanced Raman scattering (SERS) as a sensitive readout method. Proteomic analyses of readily obtained human fluids ( e.g. , serum, urine, and saliva) indicate that the diagnosis of complex diseases will be enhanced by the simultaneous measurement of multiple biomarkers from such samples.
ISSN:0003-2654
1364-5528
DOI:10.1039/c2an36128k